National cancer screening programs in place for cervical, breast, lung and colorectal cancer. Primary responsibility of the
National Screening Centre. The cost of screening programs over €100 million in 2020.
CZ has National HPV and HBV vaccination programs, fully covered by health insurance for specified age groups. A target population coverage appr 60%. Vaccination against hepatitis B covers 97% of one-year-olds.
NATIONAL CANCER SCREENING PROGRAMS (CSP)
Colorectal CSP, www.kolorektum.cz
➔ Citizens 50+, imFOBT a year (every 2 years by 55), colonoscopy every 10 years
➔ Target population coverage: 27% at 2-year intervals (48%/3-year interval)
➔10-year incidence / mortality: – 21,1% / – 28,5%
Breast CSP, www.mamo.cz
➔ Women aged 45+, MMG every 2 years
➔ Target population coverage: 58,7% at 2-year interval (66%/3-year interval)
➔ 10-year incidence / mortality: + 0,6% / – 19,7%
Cervical CSP, www.cervix.cz
➔ All adult women, cervical smear test once a year and DNA HPV test at 35 and 45 years
➔ Target population coverage: 54% at 1-year interval (79%/3-year interval)
➔10-year incidence / mortality: – 29,3% / – 15,0%
➔ Citizens aged 55 – 74, former/current smokers with smoking history at least 20 pack-years, low-dose CT, initially repeated after a year, then after 2 years
A national network of highly specialized cancer care centres was established in 2006 (Czech Comprehensive Cancer Centre
Network, CCC). Equal access to all cancer treatment modalities, incl. latest innovative system therapies and radiotherapeutic and surgical methods, is guaranteed. The network consists of 15 CCCs focused on solid tumor patients and 8 highly specialized hemato oncological care centres. Two of these centres are dedicated to complex care of pediatric cancer patients, incl. a bone marrow transplant program.
CCCs organize Regional cancer groups (RCGs). RCGs include smaller cancer centres and outpatient cancer units. This cooperation guarantees acceptance, implementation, and control of compliance.
Masaryk Memorial Cancer Institute and Motol University Hospital hold the National Cancer Center (NCC) status. NCCs are designed as coordinating scientific and research institutes. NCCs are also involved in the ERN for rare tumors and for genetic tumor risk syndromes. Both NCCs are members of the Organisation of European Cancer Institutes (OECI), Masaryk Memorial Cancer Institute holding OECI accreditation.
Cancer treatment fully covered by health insurance with the rate of availability being above EU average.
CANCER CONTROL – BUDGET
The total costs of cancer-related research projects EUR 555,844k. Almost half of the public support was used to the development of research infrastructures (EUR 170,768,000). The Ministry of Health had the largest share in the financing of specific research projects (41,5%), followed by the Czech Science Foundation/GACR (36.5%), the Ministry of Education, Youth and Sports (11.3%). Additional funds came from the Czech Technology Agency, Ministry of Industry and others.
Our areas of intervention
Main cancer statistics in the country
Cancer is a serious health problem in CZ. Yearly, more than 85k citizens are diagnosed with cancer and appr 27k die of it.
The incidence of malignant neoplasms, except non-melanoma skin, reached 58,841 (2018) newly diagnosed diseases (553.7 per 100,000 persons). For more info, see statistics.
CZ has a long-term research strategy and well-established programs for support of research organizations, infrastructures and research projects. The cancer research is part of the National Applied Medical Research and Development Support Program. Since 2015, a total amount of 659 cancer-related research projects have been registered.
The most significant part of the research projects focuses on diagnostics and cancer therapy (34%) and extending knowledge about tumors (32,6%). Although still ongoing, the projects have already resulted in 2,582 applied research results.
RESEARCH CENTERS AND INFRASTRUCTURES IN CZ
There is a high-quality research infrastructure in CZ, including Large Research Infrastructures and European Centers of Excellence.
CEITEC: Central European Institute of Technology (www.ceitec.ceu)
FNUSA-ICRC: The International Clinical Research Centre of St. Anne’s University Hospital (www.fnusa-icrc.org)
BIOCEV: Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (www.biocev.eu)
BIOMEDREG: Institute of Molecular and Translational Medicine of Palacky University (www.imtm.cz)
RCPTM: Regional Centre of Advanced Technologies and Materials (www.rcptm.com)
RECAMO: Research Centre for Applied Molecular Oncology of Masaryk Memorial Cancer Institute (www.recamo.cz)
BBMRI-CZ: Czech National Node of European biobank infrastructure BBMRI-ERIC (www.bbmri.cz)
CCP: The Czech Centre for Phenogenomics (www.biocev.eu/en/services/ the-czech-centre-for-phenogenomics.2)
Czech-BioImaging: National research infrastructure for biological and medical imaging (www.czech-bioimaging.cz)
CZECRIN: CzEch Clinical Research Infrastructure Network (www.czecrin.cz)
CZ-OPENSCREEN: National Infrastructure for Chemical Biology (www.openscreen.cz)
ELI Beamlines: Extreme Light Infrastructure (www.eli-beams.eu)
FAIR: Facility for Antiproton and Ion Research (www.ujf.cas.cz)
EATRIS-CZ: Czech National Node of European infrastructure for translational medicine (www.eatris.cz)
NCGM: National Center for Medical Genomics (www.ncgm.cz)
RECETOX RI: Research Infrastructure for Environmental Toxics Research (www.recetox.muni.cz)